Publication. Prior to publishing or presenting the results of any studies carried out under this Agreement, Everest shall submit the draft of the publication or presentation to NPLH no later than ​ Business Days prior to the planned submission for publication or presentation for NPLH’s comment. Everest shall: # consider in good faith any comments thereto provided by NPLH within such ​ day period; and # remove any Confidential Information of NPLH if requested by NPLH. NPLH shall be deemed to have consented to such publication or presentation if it has not sent any response to Everest’s request within ​ Business Days of receipt of the request by Everest by written notice to NPLH delivered pursuant to [Section 14.9]. NPLH may reasonably request a reasonable delay in publication or presentation in order to protect patentable information. If NPLH reasonably requests a delay, then Everest Portions of the exhibit, indicated by the mark “​,” were omitted and have been filed separately with the

Publication. No Credit Party will directly or indirectly publish, disclose or otherwise use in any public disclosure, advertising material, promotional material, press release or interview, any reference to the name, logo or any trademark of MCF or any of its Affiliates or any reference to this Agreement or the financing evidenced hereby, in any case except # as required by Law, subpoena or judicial or similar order, in which case the applicable Credit Party shall give Agent prior written notice of such publication or other disclosure, or # with MCF’s prior written consent.

Publication. Either party, consistent with academic standards, may publish or present the Data (as defined in Article 8 below), provided such publication or presentation does not disclose the other party’s Confidential Information. The Parties agree that any publication or presentation of Data shall appropriately cite the contributions of both Parties, using customary standards of scientific attribution. Each Party shall provide the other Party with a copy of such publication or presentation ​ prior to submission for presentation or publication to permit protection of any Confidential Information and/or patent rights, if desired and applicable. The other Party shall have ​, after receipt of said copies, to object to such proposed presentation or proposed publication because it includes patentable subject matter which needs protection or because it includes Confidential Information of such other Party. In the event that the other Party makes such objection, the publishing party shall refrain from making such publication or presentation for a maximum of ​ from date of receipt of such objection in order to allow the other Party to seek patent protection on any patentable Inventions included in the proposed publication or presentation, and the publishing Party shall remove the other Party’s Confidential Information from such publication or presentation before submitting or presenting it to any Third Party. Atara further agrees that Institute shall have the first right to publish any results of the Research Collaboration, pursuant to the terms of this Article 7. In the case of Confidential Information of Atara being results of the Research Collaboration, Institute may publish a publication or presentation containing such information after taking into account any comments by Atara in good faith and after allowing Atara to seek patent protection in accordance with this Section 7.1, unless Atara (acting reasonably) designates such information as a ‘Trade Secret’.

Publication. Either party, consistent with academic standards, may publish or present the Data (as defined in Article 8 below), provided such publication or presentation does not disclose the other party’s Confidential Information. The Parties agree that any publication or presentation of Data shall appropriately cite the contributions of both Parties, using customary standards of scientific attribution. Each Party shall provide the other Party with a copy of such publication or presentation [ * ] prior to submission for presentation or publication to permit protection of any Confidential Information and/or patent rights, if desired and applicable. The other Party shall have [ * ], after receipt of said copies, to object to such proposed presentation or proposed publication because it includes patentable subject matter which needs protection or because it includes Confidential Information of such other Party. In the event that the other Party makes such objection, the publishing party shall refrain from making such publication or presentation for a maximum of [ * ] from date of receipt of such objection in order to allow the other Party to seek patent protection on any patentable Inventions included in the proposed publication or presentation, and the publishing Party shall remove the other Party’s Confidential Information from such publication or presentation before submitting or presenting it to any Third Party. Atara further agrees that Institute shall have the first right to publish any results of the Research Collaboration, pursuant to the terms of this Article 7. In the case of Confidential Information of Atara being results of the Research Collaboration, Institute may publish a publication or presentation containing such information after taking into account any comments by Atara in good faith and after allowing Atara to seek patent protection in accordance with this Section 7.1, unless Atara (acting reasonably) designates such information as a ‘Trade Secret’.

Publication. For purposes of this [Section 13.4], the terms “publish” and “scientific presentation” (including variations such as “publication” and “presentation”) shall mean any public disclosure in the nature of a published paper, article, manuscript, report, poster, internet posting, presentation slides, abstract, outline, video, instructional material, presentation, or the like, in printed, electronic, or oral form.

Publication. Project results may not be published or referred to, in whole or in part, by RRD without the prior express written consent of Eiger. Neither Party will use the other Party’s name in connection with any publication or promotion without the other Party’s prior written consent. Notwithstanding the above, neither Party will be restricted from using the other Party’s name in filings or communications with the FDA, or other governmental or regulatory agencies, when required to do so by such agencies or by applicable law or regulation. In the event that such disclosure is required as aforesaid, the disclosing Party shall provide the other Party with notice beforehand and coordinate with the other Party with respect to the wording and timing of any such disclosure.

Publication. No Credit Party will directly or indirectly publish, disclose or otherwise use in any advertising material, promotional material, press release or interview, any reference to the name, logo or any trademark of MCF or any of its Affiliates or any reference to this Agreement or the financing evidenced hereby, in any case except # as required by Law, subpoena or judicial or similar order, in which case the applicable Credit Party shall, to the extent legally permitted to do so, give Agent prior written notice of such publication or other disclosure, or # with MCF’s prior written consent.

Publication Strategy. Within ​ of the Effective Date, the JDC will prepare a global publication strategy for the Development activities related to the Licensed Antibodies and Licensed Products Developed under the Development Program (the “Publication Strategy”) that is consistent with the Global Development Plan and any Additional Development Proposal; provided that unless otherwise agreed by the Parties, the Publication Strategy will contemplate that, as between the Parties, GSK will be primarily responsible for scientific publications related to Clinical Trials sponsored by GSK and ITEOS will be primarily responsible for scientific publications related to the Clinical Trials sponsored by ITEOS. The JDC (with consultation from the Patent Liaisons, where applicable) will review and approve such Publication Strategy, and may amend it from time to time upon agreement of the Parties. The Parties shall have no right to publish in relation to any Development activities conducted hereunder other than as specified in the Publication Strategy or otherwise in this [Section 10.8.1] (Publication Strategy); provided that either Party shall have the right to re-publish (in accordance with 10.8.4 (Re-Publication) below) or reference any publication (or information therein) previously published in accordance with the Publication Strategy and any publication (or information therein) published prior to the Execution Date. If a Party or its employees or consultants (such as clinical investigators) desires to make a publication relating to a Clinical Trial for a Licensed Product that is being conducted under the Global Development Plan or that otherwise relates to the Licensed Antibodies or Licensed Products or the activities conducted hereunder, then it shall make such request to the other Party through the JDC, and such publication shall be subject to review under [Section 10.8.2] (Review by the Parties), and the consent of such other Party, which shall not be unreasonably withheld.

Re-Publication. Once a publication or presentation has been reviewed and approved by the non-publishing Party in accordance with this [Section 10.8] (Scientific Publications), the publishing Party may use the information contained in the publication or presentation without seeking further approval so long as # such subsequent publications or presentations are released without changes to the substantive information provided therein, # are released within ​ months of the original publication, and # the information provided therein is still considered accurate and has not been superseded by other subsequent information known by such Party.

Publication; Publicity. Work Product may not be published or referred to, in whole or in part, by Consultant without the prior express written consent of Voyager. Consultant shall not use the name, logo, trade name, service mark, or trademark, or any simulation, abbreviation, or adaptation of same, or the name of Voyager or its subsidiaries for publicity, promotion, or similar non-regulatory uses without Voyager’s prior written consent.